Guide

Psych-med prior auths: the solo workflow and the appeal letter

Summary

A prior authorization is the payer's yes-before-you-fill, and as a solo prescriber you run the whole loop yourself: verify the drug needs one, pull the plan's own criteria, submit documentation that maps to those criteria, and calendar the appeal deadline the day a denial arrives. Prior auth is a treatment limitation that parity law constrains, so a denial is contestable — most overturns come from a peer-to-peer call and a tight written appeal, not from resubmitting the same form.

By Gale Editorial · Updated 2026-07-26. Every figure cited to a dated source. How we write.

What a prior authorization is, and the solo loop

A prior authorization is a payer's requirement that you get approval before it will cover a specific medication. As a solo prescriber with no billing staff, you own every step: confirming the drug needs a PA, locating the plan's own criteria, submitting clinical documentation that maps to them, and appealing a denial on time. Prior authorization is a treatment limitation, and parity law requires a plan apply it no more stringently to mental-health drugs than to medical ones 1Ref 1U.S. Department of Labor (2026).Mental Health and Substance Use Disorder Parity.That MHPAEA treats prior authorization as a non-quantitative treatment limitation that must be applied no more stringently to mental-health/SUD benefits than to medical/surgical ones, with a comparative-analysis requirement and a DOL complaint path..

That parity frame matters because it turns prior auth as a solo from a paperwork chore into a contestable process: a non-quantitative treatment limitation must be applied comparably to medical and surgical benefits, and plans must be able to produce a comparative analysis of how they apply it 1Ref 1U.S. Department of Labor (2026).Mental Health and Substance Use Disorder Parity.That MHPAEA treats prior authorization as a non-quantitative treatment limitation that must be applied no more stringently to mental-health/SUD benefits than to medical/surgical ones, with a comparative-analysis requirement and a DOL complaint path.. You do not need to litigate parity to use it — naming it in an appeal signals you know a denial is not the last word.

Where the criteria actually live

You cannot document to a standard you have not read, and every payer publishes its own coverage criteria — you just have to find them. Health plans post medical and pharmacy policies on their provider portals, and behavioral-health carve-outs post theirs on a separate portal. Pull the exact policy for the exact drug and plan before you submit; guessing at the criteria is the most common reason a first submission is denied.

These are published, not secret. A commercial plan posts its clinical policy bulletins — Aetna's, for example, lay out drug-by-drug criteria 2Ref 2Aetna (2026).Aetna Clinical Policy Bulletins.Named example of a plan publishing its own drug-by-drug clinical policy criteria on its provider portal — cited as that payer's own policy, not as what all payers do. — and UnitedHealthcare posts its policies and protocols the same way 3Ref 3UnitedHealthcare (2026).UnitedHealthcare Policies and Protocols.Named example of a plan publishing its own coverage policies and protocols on its provider portal — cited as that payer's own policy, not as what all payers do.. When a plan's behavioral-health benefit is administered by a carve-out, the authorization criteria and submission portal live there instead: Optum's behavioral-health arm runs its Provider Express portal for exactly that 4Ref 4Optum Behavioral Health (2026).Provider Express.Named example of a behavioral-health carve-out running its own authorization and claims portal, where BH criteria and submission live when a plan carves out the benefit.. Your contract controls which applies, so read the policy that governs the specific patient in front of you, not a generic summary.

The pre-submission checklist

Build a repeatable checklist so each prior auth takes minutes, not an afternoon. Verify the patient's pharmacy benefit and confirm the drug requires a PA; retrieve the plan's criterion for that drug; assemble the chart evidence the criterion asks for — diagnosis, prior trials, contraindications, and an objective severity measure; then submit through the plan's electronic PA channel and log the reference number. Attaching a validated score turns "the patient is anxious" into documentation that maps to a threshold.

A brief validated instrument does real work here. The GAD-7 — seven items scored to a total, with mild, moderate, and severe cut points — gives you an objective anchor for medical necessity that a reviewer recognizes 5Ref 5Spitzer RL, Kroenke K, Williams JB, Löwe B (2006).A brief measure for assessing generalized anxiety disorder: the GAD-7.That the GAD-7 is a validated seven-item severity measure with mild/moderate/severe cut points, usable as an objective medical-necessity anchor in a prior-authorization submission.. Record the score, the date, and the trend across visits; a rising or persistently high score documents why the requested drug is warranted far better than narrative alone. Keep a small stock of samples for the days a PA has not cleared but the patient should not go without a bridge — and check the plan's rules before you rely on that.

Step therapy, formulary exceptions, and overrides

Many denials are not "no" but "not yet" — the plan wants step therapy first, meaning documented trials of preferred agents before it covers the one you chose. When a step is medically inappropriate, request a formulary exception or step-therapy override, and document the reason the preferred drug is contraindicated, was already tried and failed, or is expected to be ineffective. The exception request, not a resubmission, is the correct next move, and each plan publishes the pathway and its timeline.

Write the exception to the plan's own exception standard, which sits alongside the coverage criteria in its published policy. The common winning pattern is short: name the preferred agent, state precisely why it is unsuitable for this patient, and attach the trial history or contraindication in the chart. An override granted on the first request beats an appeal filed after a denial, so reach for the exception pathway the moment you see a step-therapy flag rather than submitting and waiting for the "no."

REMS drugs are a separate gate

Some medications carry a federal safety program on top of any prior authorization, and confusing the two costs you time. A REMS — Risk Evaluation and Mitigation Strategy — imposes prescriber enrollment, pharmacy certification, and monitoring requirements set by the FDA, independent of what a payer requires 6Ref 6U.S. Food and Drug Administration (2026).Risk Evaluation and Mitigation Strategies (REMS).That REMS programs (e.g., clozapine, esketamine) impose FDA prescriber, pharmacy, and monitoring requirements independent of any payer prior authorization, gating dispensing until complete.. Drugs like clozapine and esketamine run through REMS, so even a covered, authorized prescription will not dispense until the REMS steps are complete.

So sequence the enrollment: complete your REMS prescriber steps and confirm the patient's pharmacy is certified before the visit where you intend to start the drug, or the patient leaves with a script that cannot be filled. Keep a short internal list of the REMS drugs you actually prescribe and their enrollment portals; for a solo practice, that list is the difference between a smooth start and a week of phone tag. A refill policy for a REMS drug also has to account for the monitoring cadence the program requires.

The appeal: peer-to-peer and the written letter

When a PA is denied, calendar the appeal deadline the day the denial arrives, then work two channels: a peer-to-peer review, where you speak to the plan's reviewer, and a written appeal that maps the denial reason to the plan's own criterion and your documentation. Most overturns come from these, not from resubmitting the identical form. Cite the specific policy language, attach the objective measures, and name parity where a limitation looks more stringent than the medical-benefit equivalent.

The written appeal has a skeleton you can template: the patient and plan identifiers, the drug and the denial reason quoted verbatim, the plan's own criterion, a point-by-point showing that the chart meets it, and a closing that requests the specific action. Where the denial reflects a limitation applied more harshly to a mental-health drug than a comparable medical one, cite the parity law and note the plan must be able to produce its comparative analysis; a parity argument raises the stakes of a rote denial 1Ref 1U.S. Department of Labor (2026).Mental Health and Substance Use Disorder Parity.That MHPAEA treats prior authorization as a non-quantitative treatment limitation that must be applied no more stringently to mental-health/SUD benefits than to medical/surgical ones, with a comparative-analysis requirement and a DOL complaint path.. If internal appeals fail, an external review — and, for parity, a complaint to the Department of Labor — are the next rungs.

Fitting prior auths into a one-person practice

The workflow only survives if it fits a solo schedule, so batch and template it. Set aside a fixed block each week for prior auths and appeals rather than interrupting sessions; keep a template for each drug you prescribe often, prefilled with the plan's criterion and the evidence it wants; and track every open PA and its deadline in one list. The solo prescriber's schedule cannot absorb ad-hoc denials, so make the administrative time a planned line, not an overflow.

Two more habits pay off. First, know which of your patients are on Medicare Advantage plans, which use prior authorization heavily for drugs and services — this differs from how original Medicare and prior auth interact, where traditional Part B and Part D rules apply and routine drug PAs are less common. Second, when you are onboarding, ask whether a service handles prior authorizations as part of practice operations so the task does not land entirely on you; Gale files and tracks prior authorizations as part of onboarding. Keep your criteria templates current, since plans update their policies annually.

Common questions

Check the patient's specific plan and formulary, not a general list. Payers publish their pharmacy policies and formularies on their provider portals, and a behavioral-health carve-out publishes its own. Confirm the requirement for the exact drug and plan before you prescribe, because the same medication can be open on one plan and restricted on another. Verifying at intake avoids a surprise denial at the pharmacy.

Documentation that maps to the plan's own criterion. Pull the specific policy, then show the diagnosis, prior medication trials and their outcomes, any contraindications to preferred agents, and an objective severity measure such as a validated screener score. Log the submission reference number and submit through the electronic channel. A submission written to match the criterion, rather than a narrative summary, is what a reviewer can approve without a callback.

Treat the denial as the start of an appeal, not the end. Calendar the appeal deadline immediately, request a peer-to-peer review, and file a written appeal that quotes the denial reason, cites the plan's own criterion, and shows point by point how your documentation meets it. Most overturns come from this, not from resubmitting the same form. Where a limitation looks more stringent than the medical equivalent, name parity.

No. A prior authorization is the payer's coverage gate; a REMS is an FDA safety program that governs prescriber enrollment, pharmacy certification, and monitoring for specific drugs like clozapine and esketamine. A prescription can be covered and authorized but still fail to dispense because the REMS steps are incomplete. Complete the REMS enrollment before the visit where you plan to start the drug, separate from any coverage question.

Batch them. Reserve a fixed weekly block for prior authorizations and appeals instead of interrupting sessions, keep a template for each drug you prescribe often prefilled with the plan's criterion, and track every open request and its deadline in a single list. Verifying benefits at intake and knowing which patients are on Medicare Advantage, which lean on prior auth heavily, prevents most of the mid-week fire drills.

Run your practice on Gale

The software is free. Gale earns one flat 3.5% all-in per paid transaction — only on transactions that actually pay. No subscription, no setup fee, no network cut.

Start or manage a practice →

References

1.U.S. Department of Labor (2026). Mental Health and Substance Use Disorder Parity. U.S. Department of Labor (EBSA). linkThat MHPAEA treats prior authorization as a non-quantitative treatment limitation that must be applied no more stringently to mental-health/SUD benefits than to medical/surgical ones, with a comparative-analysis requirement and a DOL complaint path.
2.Aetna (2026). Aetna Clinical Policy Bulletins. Aetna provider portal. link ✓Named example of a plan publishing its own drug-by-drug clinical policy criteria on its provider portal — cited as that payer's own policy, not as what all payers do.
3.UnitedHealthcare (2026). UnitedHealthcare Policies and Protocols. UnitedHealthcare provider portal. link ✓Named example of a plan publishing its own coverage policies and protocols on its provider portal — cited as that payer's own policy, not as what all payers do.
4.Optum Behavioral Health (2026). Provider Express. Optum Behavioral Health. linkNamed example of a behavioral-health carve-out running its own authorization and claims portal, where BH criteria and submission live when a plan carves out the benefit.
5.Spitzer RL, Kroenke K, Williams JB, Löwe B (2006). A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of Internal Medicine. link ✓That the GAD-7 is a validated seven-item severity measure with mild/moderate/severe cut points, usable as an objective medical-necessity anchor in a prior-authorization submission.
6.U.S. Food and Drug Administration (2026). Risk Evaluation and Mitigation Strategies (REMS). U.S. Food and Drug Administration. link ✓That REMS programs (e.g., clozapine, esketamine) impose FDA prescriber, pharmacy, and monitoring requirements independent of any payer prior authorization, gating dispensing until complete.

https://www.gale.care/for-providers/bhp-prior-auth-psych-meds · 6 sources. Competitor details are cited to dated public sources and maintained as they change; figures are estimates, not commitments. Synthetic demonstration.

← Back to for providers